Cancer Treatment / LEARNING CURVE
53
Versus Stubbornness How we can learn from failure
By Jaime Modiano, VMD, PhD
Note: This article is the basis for the pre- sentation given by Jaime Modiano, VMD, PhD, at the AAHA Phoenix 2013 Yearly Conference.
mals with cancer, providing pet owners with reasonable options ranging from palliative care to therapies with cura- tive intent. In addition to adapting protocols
D
using conventional modalities (surgery, radiation and cytotoxic chemotherapy), we have seen targeted drugs and immu- notherapy approaches developed specifi- cally for the veterinary market (Bergman 2007). However, we could argue that basic research has lagged behind these clinical advances. In particular, we have failed to address
issues such as tumor heterogeneity in some of the most common cancers we diagnose, and advances to treat highly aggressive tumors such as hemangiosar- comas have been modest. Our laboratory has emphasized these
two areas, focusing on improved under- standing of cancer pathogenesis and development stratification schemes that can improve prognosis and prediction. Here, we will review recent data focus- ing on canine lymphoma, canine osteo- sarcoma and canine hemangiosarcoma, emphasizing practical applications that
iligent clinical research over the past 30 years has allowed vet- erinarians to adapt or develop protocols to treat companion ani-
Persistence to achieve therapeutic success in cancer
Some commonly held myths about lymphoma are especially unnerving.
may be useful to practitioners in both general and specialty practice.
Canine lymphoma: One disease or many? Canine lymphoma is a heterogeneous
group of diseases that share malignant transformation of lymphocytes as a com- mon property. Several systems have been proposed to classify lymphoma over the past four decades (see Valli et al. 2011 for a review), including the modified World Health Organization (WHO) classifica- tion system, which was initially proposed in 2002 but has not yet been universally adopted. The most contemporary WHO classi-
fication system for B- and T-cell lympho- mas includes approximately 30 subtypes (ibid.). The system combines morphol- ogy, topography, immunophenotype and
Trends magazine, April 2013
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68